See more : AppTech Payments Corp. (APCX) Income Statement Analysis – Financial Results
Complete financial analysis of Collegium Pharmaceutical, Inc. (COLL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Collegium Pharmaceutical, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- PT Cahayasakti Investindo Sukses Tbk (CSIS.JK) Income Statement Analysis – Financial Results
- KINS Technology Group Inc. (KINZ) Income Statement Analysis – Financial Results
- Cyxone AB (publ) (CYXO.ST) Income Statement Analysis – Financial Results
- OVS S.p.A. (OVS.MI) Income Statement Analysis – Financial Results
- American Superconductor Corporation (AMSC) Income Statement Analysis – Financial Results
Collegium Pharmaceutical, Inc. (COLL)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.collegiumpharma.com
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 566.77M | 463.93M | 276.87M | 310.02M | 296.70M | 280.41M | 28.48M | 1.71M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 240.60M | 254.45M | 126.25M | 130.18M | 193.66M | 165.68M | 2.60M | 213.00K | 171.00K | 0.00 | 0.00 |
| Gross Profit | 326.17M | 209.49M | 150.62M | 179.84M | 103.04M | 114.74M | 25.88M | 1.50M | -171.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 57.55% | 45.15% | 54.40% | 58.01% | 34.73% | 40.92% | 90.89% | 87.55% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 3.98M | 9.45M | 9.77M | 10.34M | 8.66M | 8.57M | 14.95M | 7.98M | 14.96M | 14.16M |
| General & Administrative | 151.80M | 160.44M | 114.77M | 108.46M | 0.00 | 0.00 | 0.00 | 0.00 | 18.93M | 2.71M | 1.89M |
| Selling & Marketing | 7.41M | 11.74M | 4.19M | 5.37M | 116.45M | 126.76M | 92.76M | 80.63M | 0.00 | 0.00 | 0.00 |
| SG&A | 159.21M | 172.19M | 118.96M | 113.83M | 116.45M | 126.76M | 92.76M | 80.63M | 18.93M | 2.71M | 1.89M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -94.00K | -348.00K | 0.00 | 0.00 |
| Operating Expenses | 159.21M | 176.17M | 128.41M | 123.60M | 126.79M | 135.42M | 101.33M | 95.58M | 26.91M | 17.67M | 16.04M |
| Cost & Expenses | 399.81M | 430.61M | 254.66M | 253.78M | 320.45M | 301.10M | 103.92M | 95.79M | 26.91M | 17.67M | 16.04M |
| Interest Income | 15.62M | 1.05M | 12.00K | 232.00K | 1.94M | 1.69M | 582.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 83.34M | 63.21M | 21.01M | 28.88M | 909.00K | 20.13M | 582.00K | 94.00K | 439.00K | 252.00K | 76.00K |
| Depreciation & Amortization | 149.26M | 134.39M | 68.94M | 61.61M | 15.80M | 110.91M | 594.00K | 655.00K | 171.00K | 187.00K | 169.00K |
| EBITDA | 308.33M | 168.76M | 86.58M | 118.07M | -6.02M | 91.91M | -74.27M | -93.43M | -26.65M | -17.48M | -15.95M |
| EBITDA Ratio | 54.40% | 7.41% | 8.02% | 18.21% | -7.35% | -6.78% | -262.86% | -5,498.66% | 0.00% | 0.00% | 0.00% |
| Operating Income | 166.96M | -104.57M | -46.70M | -5.09M | -23.75M | -20.69M | -75.45M | -94.08M | -26.91M | -17.67M | -16.04M |
| Operating Income Ratio | 29.46% | -22.54% | -16.87% | -1.64% | -8.00% | -7.38% | -264.95% | -5,498.66% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -91.23M | -62.17M | -21.00M | -28.65M | 1.03M | -18.44M | 582.00K | -94.00K | -348.00K | -252.00K | -155.00K |
| Income Before Tax | 75.73M | -28.85M | -3.37M | 27.58M | -22.72M | -39.13M | -74.87M | -94.18M | -27.26M | -17.92M | -16.20M |
| Income Before Tax Ratio | 13.36% | -6.22% | -1.22% | 8.90% | -7.66% | -13.95% | -262.91% | -5,504.15% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 27.58M | -3.85M | -74.89M | 830.00K | -14.57M | -110.91M | -1.16M | 94.00K | -91.00K | 252.00K | 79.00K |
| Net Income | 48.16M | -25.00M | 71.52M | 26.75M | -8.15M | -39.13M | -74.87M | -94.18M | -27.26M | -17.92M | -16.20M |
| Net Income Ratio | 8.50% | -5.39% | 25.83% | 8.63% | -2.75% | -13.95% | -262.91% | -5,504.15% | 0.00% | 0.00% | 0.00% |
| EPS | 1.60 | -0.74 | 2.05 | 0.78 | -0.24 | -1.19 | -2.47 | -3.88 | -2.01 | -2.40 | -2.17 |
| EPS Diluted | 1.29 | -0.74 | 1.86 | 0.76 | -0.24 | -1.19 | -2.47 | -3.88 | -2.01 | -2.40 | -2.17 |
| Weighted Avg Shares Out | 33.74M | 33.83M | 34.94M | 34.41M | 33.45M | 32.88M | 30.27M | 24.26M | 13.54M | 7.47M | 7.47M |
| Weighted Avg Shares Out (Dil) | 41.79M | 33.83M | 41.05M | 35.15M | 33.45M | 32.95M | 30.27M | 24.26M | 13.54M | 7.47M | 7.47M |
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Lag Estimates
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.45 per share, missing the Zacks Consensus Estimate of $1.49 per share. This compares to earnings of $1.32 per share a year ago.
Collegium Reports First Quarter 2024 Financial Results
– Generated Q1'24 Net Revenue of $144.9 Million – – Delivered Q1'24 Record Belbuca ® Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year – – Achieved Q1'24 GAAP Net Income of $27.7 Million vs. Q1'23 GAAP Net Loss of...
Unlocking Q1 Potential of Collegium Pharmaceutical (COLL): Exploring Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Collegium Pharmaceutical (COLL), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium (COLL) to Report Q1 Earnings: Here's What to Expect
Collegium's (COLL) top line is likely to have been fueled by growth in the sales of pain drugs, Belbuca and Xtampza ER, in the first quarter of 2024.
Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
STOUGHTON, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report first quarter 2024 financial...
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
STOUGHTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the “Company”), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has called all...
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
Time to Get These 5 Top Relative Price Strength Stocks
APP, KALU, COLL, EME and TXT are five stocks with explosive relative price strength.
3 Reasons Why Collegium Pharmaceutical (COLL) Is a Great Growth Stock
Collegium Pharmaceutical (COLL) could produce exceptional returns because of its solid growth attributes.
Source: https://incomestatements.info
Category: Stock Reports